{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T04:17:29Z","timestamp":1794889049052,"version":"4.9.1"},"reference-count":59,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,2]],"date-time":"2021-01-02T00:00:00Z","timestamp":1609545600000},"content-version":"vor","delay-in-days":367,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.bbmt.2019.09.037","type":"journal-article","created":{"date-parts":[[2019,10,9]],"date-time":"2019-10-09T11:30:43Z","timestamp":1570620643000},"page":"34-43","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":174,"title":["Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen Receptor T Cell Therapy"],"prefix":"10.1016","volume":"26","author":[{"given":"Julia","family":"Ruark","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Mullane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Cleary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Cordeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evandro D.","family":"Bezerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicky","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna","family":"Voutsinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bronwen E.","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4427-3583","authenticated-orcid":false,"given":"Kathryn E.","family":"Flynn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie J.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cameron J.","family":"Turtle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Maloney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse R.","family":"Fann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merav","family":"Bar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.bbmt.2019.09.037_bib0001","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.bbmt.2019.09.037_bib0002","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.bbmt.2019.09.037_bib0003","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.bbmt.2019.09.037_bib0004","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1016\/j.bbmt.2018.12.068","article-title":"Clinical utilization of chimeric antigen receptor T cells in B cell acute lymphoblastic leukemia: an expert opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow Transplantation","volume":"25","author":"Kansagra","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"10.1016\/j.bbmt.2019.09.037_bib0005","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1016\/j.bbmt.2019.08.015","article-title":"Utilization of chimeric antigen receptor (CAR) T cell therapy in clinical practice for relapsed\/refractory aggressive B cell non-Hodgkin lymphoma: an expert panel opinion from the American Society for Transplantation and Cellular Therapy","volume":"25","author":"Jain","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"10.1016\/j.bbmt.2019.09.037_bib0006","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1016\/j.bbmt.2019.06.036","article-title":"Understanding and managing large B cell lymphoma relapses after chimeric antigen receptor T cell therapy","volume":"25","author":"Byrne","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"15","key":"10.1016\/j.bbmt.2019.09.037_bib0007","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1182\/blood-2018-11-883710","article-title":"Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy","volume":"133","author":"Hay","year":"2019","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.bbmt.2019.09.037_bib0008","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1182\/blood-2018-11-887067","article-title":"The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells","volume":"133","author":"Hirayama","year":"2019","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.bbmt.2019.09.037_bib0009","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1200\/JCO.2017.72.8519","article-title":"Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified T cells after failure of ibrutinib","volume":"35","author":"Turtle","year":"2017","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.bbmt.2019.09.037_bib0010","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.bbmt.2019.09.037_bib0011","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bbmt.2019.09.037_bib0012","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1016\/j.bbmt.2018.12.756","article-title":"Cytokine release syndrome with chimeric antigen receptor T cell therapy","volume":"25","author":"Frey","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.bbmt.2019.09.037_bib0013","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.bbmt.2019.09.037_bib0014","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.bbmt.2019.02.008","article-title":"Role of fluorodeoxyglucose positron emission tomography\/computed tomography in predicting the adverse effects of chimeric antigen receptor T cell therapy in patients with non-Hodgkin lymphoma","volume":"25","author":"Wang","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"10.1016\/j.bbmt.2019.09.037_bib0015","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov"},{"issue":"8","key":"10.1016\/j.bbmt.2019.09.037_bib0016","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov"},{"issue":"3","key":"10.1016\/j.bbmt.2019.09.037_bib0017","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/bjh.15644","article-title":"Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy","volume":"183","author":"Hay","year":"2018","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.bbmt.2019.09.037_bib0018","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.bbmt.2019.08.003","article-title":"Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells","volume":"26","author":"Cordeiro","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.bbmt.2019.09.037_bib0019","doi-asserted-by":"crossref","first-page":"614","DOI":"10.3324\/haematol.2016.150250","article-title":"Late effects of blood and marrow transplantation","volume":"102","author":"Inamoto","year":"2017","journal-title":"Haematologica"},{"issue":"23","key":"10.1016\/j.bbmt.2019.09.037_bib0020","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1093\/jnci\/djp386","article-title":"Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes","volume":"101","author":"Basch","year":"2009","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"10.1016\/j.bbmt.2019.09.037_bib0021","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/nrclinonc.2015.222","article-title":"Patient-reported outcomes in the evaluation of toxicity of anticancer treatments","volume":"13","author":"Di Maio","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"10.1016\/j.bbmt.2019.09.037_bib0022","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/jama.2017.7156","article-title":"Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment","volume":"318","author":"Basch","year":"2017","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.bbmt.2019.09.037_bib0023","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.jclinepi.2010.11.018","article-title":"Minimally important differences were estimated for six Patient-Reported Outcomes Measurement Information System-Cancer scales in advanced-stage cancer patients","volume":"64","author":"Yost","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"17","key":"10.1016\/j.bbmt.2019.09.037_bib0024","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1200\/JCO.2016.71.4410","article-title":"United States population-based estimates of Patient-Reported Outcomes Measurement Information System symptom and functional status reference values for individuals with cancer","volume":"35","author":"Jensen","year":"2017","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.bbmt.2019.09.037_bib0025","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1007\/s11136-014-0732-6","article-title":"Setting standards for severity of common symptoms in oncology using the PROMIS item banks and expert judgment","volume":"23","author":"Cella","year":"2014","journal-title":"Qual Life Res"},{"issue":"4","key":"10.1016\/j.bbmt.2019.09.037_bib0026","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1002\/cncr.31089","article-title":"PROMIS measures can be used to assess symptoms and function in long-term hematopoietic cell transplantation survivors","volume":"124","author":"Shaw","year":"2018","journal-title":"Cancer"},{"issue":"17","key":"10.1016\/j.bbmt.2019.09.037_bib0027","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.1182\/blood-2010-11-319509","article-title":"Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium","volume":"117","author":"Pidala","year":"2011","journal-title":"Blood"},{"issue":"Suppl 2","key":"10.1016\/j.bbmt.2019.09.037_bib0028","doi-asserted-by":"crossref","first-page":"S138","DOI":"10.21037\/tlcr.2018.03.09","article-title":"Patient-related outcomes with the use of checkpoint inhibitors for the treatment of metastatic non-small cell lung cancer","volume":"7","author":"Malhotra","year":"2018","journal-title":"Transl Lung Cancer Res"},{"issue":"1","key":"10.1016\/j.bbmt.2019.09.037_bib0029","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jpainsymman.2019.03.015","article-title":"Patient-reported outcomes for cancer patients receiving checkpoint inhibitors: opportunities for palliative care: a systematic review","volume":"58","author":"Hall","year":"2019","journal-title":"J Pain Symptom Manage"},{"issue":"8","key":"10.1016\/j.bbmt.2019.09.037_bib0030","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S1470-2045(17)30421-7","article-title":"Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial","volume":"18","author":"Harrington","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bbmt.2019.09.037_bib0031","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ejca.2018.05.005","article-title":"Evaluation of health-related quality of life and symptoms in patients with advanced non-squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 057","volume":"102","author":"Reck","year":"2018","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.bbmt.2019.09.037_bib0032","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.jtho.2017.10.029","article-title":"Impact of nivolumab versus docetaxel on health-related quality of life and symptoms in patients with advanced squamous non-small cell lung cancer: results from the CheckMate 017 Study","volume":"13","author":"Reck","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.bbmt.2019.09.037_bib0033","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ctrv.2018.08.001","article-title":"Patient-reported outcomes with nivolumab in advanced solid cancers","volume":"70","author":"Tykodi","year":"2018","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"10.1016\/j.bbmt.2019.09.037_bib0034","doi-asserted-by":"crossref","first-page":"e155","DOI":"10.1016\/j.bbmt.2018.11.025","article-title":"Patient-reported outcomes with chimeric antigen receptor T cell therapy: challenges and opportunities","volume":"25","author":"Chakraborty","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"10.1016\/j.bbmt.2019.09.037_bib0035","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.jclinepi.2010.04.011","article-title":"The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005-2008","volume":"63","author":"Cella","year":"2010","journal-title":"J Clin Epidemiol"},{"issue":"11","key":"10.1016\/j.bbmt.2019.09.037_bib0036","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.jclinepi.2009.11.021","article-title":"Representativeness of the Patient-Reported Outcomes Measurement Information System Internet panel","volume":"63","author":"Liu","year":"2010","journal-title":"J Clin Epidemiol"},{"issue":"11","key":"10.1016\/j.bbmt.2019.09.037_bib0037","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.jclinepi.2010.04.012","article-title":"Relative to the general US population, chronic diseases are associated with poorer health-related quality of life as measured by the Patient-Reported Outcomes Measurement Information System (PROMIS)","volume":"63","author":"Rothrock","year":"2010","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"10.1016\/j.bbmt.2019.09.037_bib0038","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/cncr.25514","article-title":"Screening for major depression in cancer outpatients: the diagnostic accuracy of the 9-item patient health questionnaire","volume":"117","author":"Thekkumpurath","year":"2011","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.bbmt.2019.09.037_bib0039","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1097\/01.MLR.0000093487.78664.3C","article-title":"The Patient Health Questionnaire-2: validity of a two-item depression screener","volume":"41","author":"Kroenke","year":"2003","journal-title":"Med Care"},{"issue":"6","key":"10.1016\/j.bbmt.2019.09.037_bib0040","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1002\/pon.4681","article-title":"The Generalized Anxiety Disorder Screener (GAD-7) and the anxiety module of the Hospital and Depression Scale (HADS-A) as screening tools for generalized anxiety disorder among cancer patients","volume":"27","author":"Esser","year":"2018","journal-title":"Psychooncology"},{"key":"10.1016\/j.bbmt.2019.09.037_bib0041","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.genhosppsych.2015.11.005","article-title":"Screening for anxiety disorders with the GAD-7 and GAD-2: a systematic review and diagnostic metaanalysis","volume":"39","author":"Plummer","year":"2016","journal-title":"Gen Hosp Psychiatry"},{"issue":"9","key":"10.1016\/j.bbmt.2019.09.037_bib0042","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.3324\/haematol.2018.192930","article-title":"Patient-reported outcomes and health status associated with chronic graft-versus-host disease","volume":"103","author":"Lee","year":"2018","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.bbmt.2019.09.037_bib0043","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.bbmt.2018.09.040","article-title":"Employment, insurance, and financial experiences of patients with chronic graft-versus-host disease in North America","volume":"25","author":"Khera","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"10.1016\/j.bbmt.2019.09.037_bib0044","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1158\/1055-9965.EPI-12-0740","article-title":"Mental and physical health-related quality of life among U.S. cancer survivors: population estimates from the 2010 National Health Interview Survey","volume":"21","author":"Weaver","year":"2012","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"4","key":"10.1016\/j.bbmt.2019.09.037_bib0045","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.jgo.2017.02.009","article-title":"Activities, function, and health-related quality of life (HRQOL) of older adults with cancer","volume":"8","author":"Pergolotti","year":"2017","journal-title":"J Geriatr Oncol"},{"issue":"17","key":"10.1016\/j.bbmt.2019.09.037_bib0046","doi-asserted-by":"crossref","first-page":"4723","DOI":"10.1182\/blood-2011-04-348730","article-title":"Adverse psychological outcomes in long-term survivors of hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study (BMTSS)","volume":"118","author":"Sun","year":"2011","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bbmt.2019.09.037_bib0047","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1002\/pon.1581","article-title":"Neuropsychological functioning and quality of life during the first year after completing chemotherapy for breast cancer","volume":"19","author":"Reid-Arndt","year":"2010","journal-title":"Psychooncology"},{"key":"10.1016\/j.bbmt.2019.09.037_bib0048","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3389\/fonc.2015.00059","article-title":"A meta-analysis of cognitive impairment and decline associated with adjuvant chemotherapy in women with breast cancer","volume":"5","author":"Ono","year":"2015","journal-title":"Front Oncol"},{"issue":"17","key":"10.1016\/j.bbmt.2019.09.037_bib0049","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1200\/JCO.2010.33.9119","article-title":"Prospective neurocognitive function over 5 years after allogeneic hematopoietic cell transplantation for cancer survivors compared with matched controls at 5 years","volume":"29","author":"Syrjala","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2019.09.037_bib0050","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.critrevonc.2017.08.001","article-title":"Cognitive impairment and chemotherapy: a brief overview","volume":"118","author":"Vitali","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"issue":"6","key":"10.1016\/j.bbmt.2019.09.037_bib0051","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.bbmt.2010.01.003","article-title":"Impact of delirium on distress, health-related quality of life, and cognition 6 months and 1 year after hematopoietic cell transplant","volume":"16","author":"Basinski","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"10.1016\/j.bbmt.2019.09.037_bib0052","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1007\/s40263-018-0582-9","article-title":"Neurotoxicity associated with CD19-targeted CAR-T cell therapies","volume":"32","author":"Gust","year":"2018","journal-title":"CNS Drugs"},{"key":"10.1016\/j.bbmt.2019.09.037_bib0053","unstructured":"Hunter BD, Jacobson CA. CAR T-cell associated neurotoxicity: mechanisms, clinicopathologic correlates, and future directions [e-pub ahead of print]. J Natl Cancer Inst."},{"issue":"4","key":"10.1016\/j.bbmt.2019.09.037_bib0054","first-page":"485","article-title":"Objective and self-reported cognitive dysfunction in breast cancer women treated with chemotherapy: a prospective study","volume":"21","author":"Biglia","year":"2012","journal-title":"Eur J Cancer Care (Engl)"},{"issue":"1","key":"10.1016\/j.bbmt.2019.09.037_bib0055","first-page":"20","article-title":"Predictors of subjective versus objective cognitive functioning in patients with stable grades II and III glioma","volume":"2","author":"Gehring","year":"2015","journal-title":"Neurooncol Pract"},{"issue":"6","key":"10.1016\/j.bbmt.2019.09.037_bib0056","doi-asserted-by":"crossref","first-page":"361","DOI":"10.3109\/10673220903465700","article-title":"Psycho-oncology","volume":"17","author":"Breitbart","year":"2009","journal-title":"Harv Rev Psychiatry"},{"issue":"Suppl 1)","key":"10.1016\/j.bbmt.2019.09.037_bib0057","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1634\/theoncologist.12-S1-4","article-title":"Cancer-related fatigue: the scale of the problem","volume":"12(","author":"Hofman","year":"2007","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.bbmt.2019.09.037_bib0058","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/sj.bmt.1704561","article-title":"A prospective study of health-related quality of life, fatigue, anxiety and depression 3-5 years after stem cell transplantation","volume":"34","author":"Hjermstad","year":"2004","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.bbmt.2019.09.037_bib0059","first-page":"123","article-title":"Clinical characteristics, pathophysiology, and management of noncentral nervous system cancer-related cognitive impairment in adults","volume":"65","author":"Wefel","year":"2015","journal-title":"CA Cancer J Clin"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879119306573?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879119306573?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:10:12Z","timestamp":1761059412000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879119306573"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S1083879119306573"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2019.09.037","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen Receptor T Cell Therapy","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2019.09.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}